Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.
Leuprorelin
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Lupron, Eligard, Lucrin, Lupaneta, others |
| Other names | leuprolide, leuprolidine, A-43818, Abbott-43818, DC-2-269, TAP-144 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a685040 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | implant, subcutaneous, intramuscular |
| Drug class | GnRH analogue; GnRH agonist; Antigonadotropin |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | 3 hours |
| Excretion | Kidney |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.161.466 |
| Chemical and physical data | |
| Formula | C59H84N16O12 |
| Molar mass | 1209.421 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Leuprorelin, also known as leuprolide, is a manufactured version of a hormone used to treat prostate cancer, breast cancer, endometriosis, uterine fibroids, for early puberty, or as part of transgender hormone therapy.[10][11] It is given by injection into a muscle or under the skin.[10]
Leuprorelin is in the gonadotropin-releasing hormone (GnRH) analogue family of medications.[10] It works by decreasing gonadotropins and therefore decreasing testosterone and estradiol.[10] Common side effects include hot flashes, unstable mood, trouble sleeping, headaches, and pain at the site of injection.[10] Other side effects may include high blood sugar, allergic reactions, and problems with the pituitary gland.[10] Use during pregnancy may harm foetal development.[10]
Leuprorelin was patented in 1973 and approved for medical use in the United States in 1985.[10][12] It is on the World Health Organization's List of Essential Medicines.[11] It is sold under the brand name Lupron among others.[10]
- ^ ELIGARD (Mundipharma Pty Ltd) Department of Health and Aged Care. Retrieved 30 March 2023
- ^ "Product monograph brand safety updates". Health Canada. February 2024. Retrieved 24 March 2024.
- ^ "Regulatory Decision Summary for Eligard". Drug and Health Products Portal. 21 September 2023. Retrieved 2 April 2024.
- ^ Cite error: The named reference
Lupron FDA labelwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Eligard FDA labelwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Fensolvi FDA labelwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Viadur FDA labelwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Lupron Depot FDA labelwas invoked but never defined (see the help page). - ^ "Camcevi EPAR". European Medicines Agency (EMA). 22 March 2022. Retrieved 21 June 2022.
- ^ a b c d e f g h i "Leuprolide Acetate". The American Society of Health-System Pharmacists. Archived from the original on 23 December 2016. Retrieved 8 December 2016.
- ^ a b World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 514. ISBN 978-3-527-60749-5. Archived from the original on 20 June 2021. Retrieved 19 September 2020.
Previous Page Next Page
